“…In Table 3, we summarize findings from studies comparing serum fucose and fucosylated glycan profiles from healthy individuals vs. breast, oral/head and neck, HCC, ovarian, CRC, pancreatic, lung and prostate cancer patients. Several of these studies suggest diagnostic potential for serum L-fucose levels, which have been found to be elevated in cancer patient sera in breast [53,54,55], oral/head and neck [56,57,58,59,60,61], HCC [62,63,64,65], CRC [66,67], and ovarian [55,68] cancer patients compared with healthy individuals. Specific fucosylated glycoconjugates have been found to also have potential diagnostic utility.…”